Company news
Xenetic Biosciences, Inc. news in 2022
Xenetic Biosciences, Inc.'s news releases, calls and decks from 2022, newest first.
Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform
November 15, 2022
Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
November 9, 2022
Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics
October 10, 2022
Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board
October 3, 2022
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 6, 2022
Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
August 11, 2022
Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer
August 1, 2022
Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study
July 6, 2022
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event
June 1, 2022
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022
Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
May 11, 2022
Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities
April 26, 2022
Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update
March 22, 2022